Healthcare DIVE November 6, 2024
Emily Olsen

Still, gross spending on the drugs increased by more than 500% from 2019 to 2023, according to the health policy research firm.

Dive Brief:

  • Few Medicaid programs cover GLP-1 drugs for obesity as states grapple with the medications’ high cost, according to an analysis by KFF.
  • Thirteen programs for the safety-net coverage include the newer glucagon-like peptide-1 drugs for weight loss as of August 2024, the health policy research firm found.
  • Still, GLP-1 prescriptions and spending in Medicaid are increasing quickly. From 2019 to 2023, the number of prescriptions spiked by more than 400%, while gross spending soared by more than 500%.

Dive Insight:

GLP-1s currently make up a small portion of Medicaid prescriptions and spending...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, Govt Agencies, Insurance, Medicaid, Pharma / Biotech, States, Survey / Study, Trends
Related Articles:
CMS Launches New Program for Mental Health, OUD Treatment
Georgia Medicaid shakeup could force 3 in 4 beneficiaries to change plans: Centene CEO
Hospital Margins Rebounded in 2023, But Rural Hospitals and Those With High Medicaid Shares Were Struggling More Than Others
Proposed Rule Would Expand Medicare And Medicaid Coverage For Anti-Obesity Medications
Opinion: How AI can help bring better care to Medicaid patients

Share This Article